Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 5Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Carcinoma 1Brain Neoplasms 1Alzheimer Disease 1

Interventions

Temozolomide 15Irinotecan 12Cyclophosphamide 11dinutuximab 8naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × Transurethral Resection of Bladder × Clear all
NCT06172296 2026-05-27

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡